hepato pulmonary syndrome
TRANSCRIPT
![Page 1: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/1.jpg)
![Page 2: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/2.jpg)
Hepatopulmonary syndrome is considered present when the following triad exists
Liver disease Impaired oxygenation Intrapulmonary vascular abnormalities,
referred to as intrapulmonary vascular dilatations (IPVDs)
![Page 3: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/3.jpg)
Failure of damaged liver to clear circulating pulmonary vasodilators
Production of circulating vasodilator by damaged liver
Inhibition of circulating vasoconstrictive substance by damaged liver
Key priming factor : Increased endogenous NO production
![Page 4: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/4.jpg)
Possible Mediators of Vascular Dilatation in HPS
Increased Pulmonary Vasodilators
Prostaglandin I2 or E1
VIP
Nitric oxide
Platelet-activating factor
Decreased Vasoconstrictors
Endothelin
Tyrosine
Serotonin
![Page 5: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/5.jpg)
![Page 6: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/6.jpg)
Clinical Features
Dyspnoea
Spider nevi
Clubbing
Cyanosis
Severe hypoxaemia
Orthodeoxia
Platypnoea
Clinical features
![Page 7: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/7.jpg)
Platypnea –Increase in dyspnea that is induced by moving into an upright position and relieved by recumbency
Orthodeoxia – Decrease in the arterial oxygen tension (by > 4 mmHg) or arterial oxyhemoglobin desaturation (by > 5%) when the patient moves from a supine to an upright position, which is improved by returning to the recumbent position
![Page 8: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/8.jpg)
It is hypothesized that platypnea and orthodeoxia are caused by preferential perfusion of IPVDs in the lung bases when the patient is upright
Hypoxemia is due to intrapulmonary vascular dilatations which range in diameter from 15 to 160 microns
Shunting through the IPVDs leads to ventilation-perfusion mismatch & oxygen diffusion limitation
![Page 9: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/9.jpg)
Ventilation-perfusion mismatch is a consequence of increased blood flow through the IPVDs in the setting of preserved alveolar ventilation
Results in the passage of mixed venous blood into the pulmonary veins
![Page 10: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/10.jpg)
The oxygen diffusion limitation is a consequence of diffusion-perfusion impairment
At room air, the partial pressure of O2 is insufficient for equilibration with blood moving near the center of the alveolar capillary because of the increased diameter of the IPVDs
Supplemental oxygen increases the driving pressure of O2 & improves oxygenation, which distinguishes IPVDs as physiologic rather than anatomic shunts
![Page 11: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/11.jpg)
![Page 12: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/12.jpg)
![Page 13: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/13.jpg)
ABG analysis : pt sitting in upright posture
PaO2 : <80 mmHgSensitive measure
Elevated alveolar-arterial (A-a) oxygen gradient
Defined as ≥15 mmHg when breathing room air
![Page 14: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/14.jpg)
Contrast-enhanced echocardiography: more sensitive , less invasive
Technetium-99m-labeled macro aggregated albumin scanning
Pulmonary arteriography
![Page 15: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/15.jpg)
Performed by injecting agitated saline or indocyanine green dye intravenously
Normally the contrast opacifies only the right heart chambers because it is filtered by the pulmonary capillary bed
Contrast may opacify the left heart chambers if a right-to-left intracardiac or intrapulmonary shunt is present
Intracardiac shunt : contrast appears in the left heart within 3 heart beats after injection
Intrapulmonary shunt : contrast generally appears in the left heart 3 to 6 heart beats after its appearance in the right heart
![Page 16: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/16.jpg)
It involves intravenously injecting albumin macroaggregates that should be trapped in the pulmonary capillary bed, since the 20 micron diameter of the macroaggregates exceeds the normal pulmonary capillary diameter of 8 to 15 microns
Scans that identify uptake of the radionuclide by the kidneys and/or brain suggest that the macroaggregates passed through either an intrapulmonary or intracardiac shunt
The proportion of radionuclide taken up may be used to quantify the shunt
Limitation Inability to distinguish intrapulmonary from intracardiac
shunts lower sensitivity
![Page 17: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/17.jpg)
Two patterns of IPVD:
TypeⅠor diffuse pattern▪ Minimal typeⅠ : normal vessels or diffuse and tenuous spider
web vascular abnormalities▪ Advanced type : a spongy or blotchy appearanceⅠ
TypeⅡ or focal pattern: arteriovenous malformations
![Page 18: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/18.jpg)
![Page 19: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/19.jpg)
CXR may show increased bibasilar interstitial marking
Spirometry : normal
![Page 20: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/20.jpg)
![Page 21: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/21.jpg)
Long term oxygen therapy
Transjugular intrahepatic portosystemic shunt (TIPS) placement has been associated with improvement of HPS in several case reports
![Page 22: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/22.jpg)
Liver transplantation is indicated for patients with incapacitating hypoxemia due to HPS
Normalization of the abnormal oxygenation Require up to 15 months
![Page 23: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/23.jpg)
• HPS is characterized by defects in oxygenation due to pulmonary abnormalities associated with chronic liver disease.
• Dyspnea and hypoxemia can be severe and often worsen in the upright position.
• Gross dilatation of the precapillary and capillary vessels occurs with ventilation–perfusion mismatch.
• The syndrome usually improves after liver transplantation.
![Page 24: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/24.jpg)
![Page 25: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/25.jpg)
![Page 26: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/26.jpg)
![Page 27: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/27.jpg)
![Page 28: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/28.jpg)
![Page 29: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/29.jpg)
![Page 30: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/30.jpg)
![Page 31: Hepato pulmonary syndrome](https://reader035.vdocument.in/reader035/viewer/2022062319/556b0309d8b42a2a4f8b519d/html5/thumbnails/31.jpg)